@article{oai:shiga-med.repo.nii.ac.jp:00004188,
 author = {堀部, 佳代 and 森野, 勝太郎 and 宮澤, 伊都子 and 近藤, 慶子 and 佐藤, 大介 and 大橋, 夏子 and 井田, 昌吾 and 柳町, 剛司 and 吉村, 雅寛 and 井藤, 隆太 and 村田, 喜代史 and 三浦, 克之 and 有馬, 久富 and 藤田, 征弘 and 卯木, 智 and 前川, 聡 and HORIBE, Kayo and MORINO, Katsutaro and MIYAZAWA, Itsuko and Tanaka-Mizuno, Sachiko and KONDO, Keiko and SATO, Daisuke and OHASHI, Natsuko and IDA, Shogo and YANAGIMACHI, Tsuyoshi and YOSHIMURA, Masahiro and ITOH, Ryuta and MURATA, Kiyoshi and MIURA, Katsuyuki and ARIMA, Hisatomi and FUJITA, Yukihiro and UGI, Satoshi and MAEGAWA, Hiroshi},
 journal = {Diabetes research and clinical practice},
 month = {Feb},
 note = {pdf, Aim:
We aimed to determine whether SGLT2 inhibitor dapagliflozin treatment affects body composition and amino acid (AA) metabolism., Methods:
Fifty-two overweight patients treated by oral antidiabetic agents were randomly assigned to dapagliflozin (Dapa) or a standard treatment (Con) and followed for 24 weeks. The primary outcome was the change in body mass (BM) between baseline and week 24. Body composition, intrahepatic triglyceride (IHTG) content, and plasma AA concentrations were examined as secondary outcomes., Results:
The change in BM was significantly larger in the Dapa than in the Con group, with a difference in the mean change of -1.72 kg (95 %CI: -2.85, -0.59; P = 0.004) between the groups. Total fat mass was reduced by dapagliflozin treatment, but fat-free mass was maintained. IHTG content was significantly reduced in the Dapa than in the Con (P = 0.033). Changes in AAs showed small differences between the groups, but only serine concentrations were significantly reduced in the Dapa. Intra-group analysis showed that positive associations were observed between changes in branched chain AA concentrations and body composition only in the Dapa., Conclusions:
Dapagliflozin treatment causes a reduction in BM mainly by reducing fat mass. AA metabolism shows subtle changes with dapagliflozin treatment., Journal Article},
 title = {Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.},
 volume = {186},
 year = {2022}
}